Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Igc Pharma Inc (NY: IGC )

0.3560 +0.0035 (+0.99%)
Official Closing Price Updated: 8:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Igc Pharma Inc

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
420 with CNW — New Study Finds Medical Cannabis Legalization Reduces Use of Opioids by Cancer Patients
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
420 with CNW — New Study Finds Medical Cannabis Legalization Reduces Use of Opioids by Cancer Patients
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Applauds Milestone Development for Medical Cannabis Industry
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
CannabisNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Applauds Milestone Development for Medical Cannabis Industry
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
The Future Of The Indian Market
India has an estimated 26,000 startups, making it the third-largest startup ecosystem in the world, recording consolidated inflows of over $36 billion in the past 3 years. 
Via Talk Markets
BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Commences Trial Evaluating IGC-AD1 for the Treatment of Alzheimer’s-Related Symptoms
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Present at RHK 2022 Disruptive Growth Conference
Via Investor Brand Network
IGC Starts Phase 2 Clinical Trials Of THC Based Drug Candidate For The Treatment Of Agitation In Dementia From Alzheimer's Disease
India Globalization Capital, Inc. (AMEX:IGC) has begun “A phase 2, multi-center, double-blind, randomized, placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants... 
Via Benzinga
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease
From India Globalization Capital, Inc.
Via Business Wire
InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Numbers for Q2
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials
India Globalization Capital, Inc. (AMEX:IGC) reported its second fiscal quarter 2023 financial results, revealing revenue of $202,000, a 261% increase compared to $56,000 in the same quarter of 2022. 
Via Benzinga
IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022
From India Globalization Capital, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning. 
Via InvestorPlace
IGC Announces Issuance Of Second Patent For The Treatment Of Alzheimer's Using THC
India Globalization Capital, Inc. (AMEX:IGC) announced that the United States Patent and Trademark Office issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme... 
Via Benzinga
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
From India Globalization Capital, Inc.
Via Business Wire
IGC Announces Results of its 2022 Annual Stockholders Meeting
From India Globalization Capital, Inc.
Via Business Wire
IGC Stock Slightly Up On Q1 2023 Revenue Growth Of 175%, What About Gross Profit?
India Globalization Capital, Inc. (AMEX:IGC) revenue in Q1 2023 was approximately $212,000 an increase of 175% compared to $77,000 in the same quarter of 2022. 
Via Benzinga
IGC Reports Financial Results for the Quarter Ended June 30, 2022
From India Globalization Capital, Inc.
Via Business Wire
IGC Revenue Drops 55.8% In Fiscal 2022, What About Gross Profit?
India Globalization Capital, Inc. (AMEX:IGC) revenue in fiscal 2022 was $397,000, a 55.8% decrease compared to $898,000 in fiscal 2021. 
Via Benzinga
IGC Reports Financial Results for Fiscal Year Ended March 31, 2022
From India Globalization Capital, Inc.
Via Business Wire
IGC Acquires Exclusive Rights For A Potential Alzheimer's Drug Development Candidate
One of subsidiaries of India Globalization Capital, Inc. (NYSE: IGC) reached an intellectual property license agreement for a potential Alzheimer’s drug development candidate. 
Via Benzinga
IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate
From India Globalization Capital, Inc.
Via Business Wire
44 Stocks Moving In Friday's Mid-Day Session
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial. 
Via Benzinga
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. 
Via Benzinga
69 Biggest Movers From Yesterday
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday. 
Via Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) jumped 65% to $0.6382. 
Via Benzinga
IGC Receives U.S. Patent For Method And Composition For Treating Seizure Disorders, Utilizing CBD
United States Patent and Trademark Office issued a patent (#11,351,152) to the India Globalization Capital, Inc. (AMEX:IGC) titled “Method and Composition for Treating Seizure Disorders.” 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're starting off another day of trading with an overview of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
18 Stocks Moving in Thursday's Pre-Market Session
Gainers View, Inc. (NASDAQ: VIEW) rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.